A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Conditions
Small Cell Lung Cancer
Conditions: official terms
Small Cell Lung Carcinoma
Conditions: Keywords
SCLC
Study Type
Interventional
Study Phase
Phase 2/Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
Type: Drug
Overall Status
Recruiting
Summary
Comparison of two combination chemotherapies in the treatment of patients with SLCL
Detailed Description
Comparison of two combination chemotherapies in the treatment of patients with SLCL

The combination chemotherapies for this study are Carboplatin plus Irinotecan versus Carboplatin plus Etoposide.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- cytological or histological proven SCLC Stage I or II at 1st diagnosis

- no prior chemotherapy

- measurable tumor disease

- karnofsky performance 70

Exclusion Criteria:

- second malignancy ( except basal cell carcinoma, CA in situ Cervix uteri)

- NYHA III

- chronic diarrhea, obstructive bowel syndrome
Location
Hematology & Oncology Charité CBF Berlin, Germany
Berlin, Germany
Status: Recruiting
Contact: Ulrich Keilholz, MD - +49-30-8445-3596 - ulrich.keilholz@charite.de
Start Date
October 2001
Completion Date
December 2006
Sponsors
Charite University, Berlin, Germany
Source
Charite University, Berlin, Germany
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page